Drug Detail

Information about LEE011

Generic Name
IND	LEE011
Brand Name (US)
Manufacturer	Novartis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	Cdk4 & Cdk6 inhibitor

LEE011 is a potent and selective inhibitor of Cdk4/cyclin D1 kinase and Cdk6.
Alterations in CDKN2A have been described in GIST. CDKN2A signaling is dependent on Cdk4 and Cdk6 represents an alternate pathway to Cdk4. Thus, it is hypothesized that inhibiting Cdk4 might be an effective strategy against GIST.